Skip to main content
Edwards Lifesciences Logo

보도 자료

newsroom banner image
newsroom banner image
newsroom banner image

Edwards Lifesciences to Present at the 44th Annual TD Cowen Healthcare Conference

Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve

Edwards Lifesciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

EDWARDS LIFESCIENCES OUTLINES GROWTH STRATEGY AT ANNUAL INVESTOR CONFERENCE

CLASP IID ONE-YEAR DATA CONFIRM SAFETY AND EFFICACY OF EDWARDS PASCAL SYSTEM FOR DEGENERATIVE MITRAL REGURGITATION

TRISCEND II SIX-MONTH DATA FOR FIRST 150 PATIENTS SUCCESSFULLY DEMONSTRATE SAFETY AND EFFICACY OF EDWARDS EVOQUE SYSTEM FOR SEVERE TRICUSPID REGURGITATION

FIVE-YEAR DATA FROM PARTNER 3 TRIAL DEMONSTRATE EXCELLENT SURVIVAL FOR PATIENTS RECEIVING EDWARDS SAPIEN 3 VALVE

EDWARDS EVOQUE TRANSCATHETER TRICUSPID VALVE REPLACEMENT SYSTEM RECEIVES CE MARK

EDWARDS LIFESCIENCES TO PRESENT AT THE 2023 WELLS FARGO HEALTHCARE CONFERENCE

DATA FROM BENCHMARK REGISTRY DEMONSTRATE IMPROVED TAVR EFFICIENCY WITH PRESERVED PATIENT SAFETY

EDWARDS' AORTIC VALVE WITH RESILIA TISSUE SHOWS FAVORABLE DURABILITY, SAFETY AND EFFICACY OUTCOMES IN SEVEN YEAR DATA

EDWARDS HIGHLIGHTS NEW DATA AT ACC RELATED TO LIFETIME MANAGEMENT OF AORTIC STENOSIS

EDWARDS LIFESCIENCES TO PRESENT AT THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

EDWARDS LIFESCIENCES OUTLINES GROWTH STRATEGY AT ANNUAL INVESTOR CONFERENCE

EDWARDS ANNOUNCES ONE-YEAR DATA ON TRANSFEMORAL TRANSCATHETER TRICUSPID VALVE REPLACEMENT

EDWARDS ANNOUNCES SIX-MONTH DATA CONFIRMING TEER AS SAFE AND EFFECTIVE FOR DMR IN FIRST HEAD-TO-HEAD TRIAL

EDWARDS PASCAL PRECISION TRANSCATHETER VALVE REPAIR SYSTEM RECEIVES FDA APPROVAL FOR DEGENERATIVE MITRAL REGURGITATION

EDWARDS PASCAL PRECISION TRANSCATHETER MITRAL AND TRICUSPID VALVE REPAIR SYSTEM RECEIVES CE MARK

EDWARDS LIFESCIENCES TO PRESENT AT THE BERNSTEIN 38TH ANNUAL STRATEGIC DECISIONS CONFERENCE

EDWARDS MITRIS RESILIA VALVE RECEIVES FDA APPROVAL FOR MITRAL REPLACEMENT SURGERIES

EDWARDS LIFESCIENCES TO PRESENT AT THE 40TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

EDWARDS RECEIVES FDA APPROVAL FOR SAPIEN 3 WITH ALTERRA PRESTENT FOR TRANSCATHETER PULMONIC VALVE REPLACEMENT

Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference

Edwards Announces Six-month Data From Transcatheter Tricuspid Replacement Program

TAVR with SAPIEN 3 Demonstrated as Economically Dominant Treatment Strategy Compared to Surgery in Partner 3 Analysis

Edwards Lifesciences initiates $100 million social impact investment fund to advance racial equity

Study Data Presented at TVT on the Economics of Minimalist TAVR, PARTNER 3 Bicuspid TAVR

Edwards Receives Clearance For Hypotension Prediction Index Software For Noninvasive Acumen IQ Cuff

Clinical Data Updates On Edwards' Transcatheter Mitral, Tricuspid Programs Presented At EuroPCR

Real-World Data Confirm Excellent Results For Bicuspid Patients Treated With Edwards SAPIEN 3 TAVR

Edwards RESILIA Tissue Aortic Valve Demonstrates Favorable Safety and Efficacy at Five Years

Edwards Treats First Patient In U.S. Clinical Trial Evaluating Minimally Invasive Device For Mitral Valve Disease

Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference

Edwards' KONECT RESILIA Aortic Valved Conduit Receives FDA Approval For Complex Aortic Valve Surgeries

Edwards Lifesciences Agrees To Global Transcatheter Litigation Settlement With Abbott

Edwards PASCAL Transcatheter Valve Repair System Receives European Approval For Tricuspid Repair

Edwards Pauses Enrollments In Pivotal Mitral, Tricuspid Trials In Response To Hospitals' Focus On COVID-19

Edwards Lifesciences To Present At The Cowen 40th Annual Healthcare Conference

Edwards Lifesciences' Every Heartbeat Matters Philanthropic Initiative Expanding To Reach More Patients

Edwards Lifesciences To Present At The 38th Annual J.P. Morgan Healthcare Conference

Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference

Edwards SAPIEN 3 TAVR Demonstrates Significant Health Status Improvements for Low-Risk Patients

Edwards Lifesciences To Present At The 2019 Wells Fargo Healthcare Conference

Edwards Lifesciences To Present At The Goldman Sachs 40th Annual Global Healthcare Conference

Edwards Lifesciences Recommends Stockholders Reject "Mini-Tender Offer" By TRC Capital Corporation

Edwards Lifesciences' Every Heartbeat Matters Charitable Initiative On Track to Impact 1.5 Million Underserved People By 2020

Boston Scientific, Edwards Lifesciences Agree To Global Litigation Settlement

Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference

Edwards Receives Clearance For HemoSphere Platform With Intelligent Decision-Support Tools

Edwards Announces Start Of U.S. Study Of Self-Expanding Transcatheter Heart Valve

Edwards Lifesciences' Philanthropy Exceeds Every Heartbeat Matters Goal To Impact One Million Underserved People Ahead Of Schedule

Edwards Lifesciences To Present At The 13th Annual Wells Fargo Healthcare Conference

Edwards Lifesciences To Present at 38th Annual Canaccord Genuity Growth Conference

Edwards Lifesciences To Present At The Bernstein 34th Annual Strategic Decisions Conference

Real-World Evidence Confirms Clinical Trial Outcomes For Patients Treated With Edwards SAPIEN 3 Valve

Edwards Prevails In U.S. Patent Office Review That Finds Boston Scientific Transcatheter Valve Patent Claims Invalid

Edwards Completes Enrollment In PARTNER 3 Low-Risk CT Sub-Study, Updates Timeline For SAPIEN 3 Ultra System Launch In Europe

Edwards Lifesciences To Present At The Cowen 38th Annual Health Care Conference

Edwards Lifesciences To Present At The 36th Annual J.P. Morgan Healthcare Conference

연락처

투자자

(+1).949.250.6826

Mark Wilterding
(SVP, 투자 홍보)

미디어

(+1).949.250.5070

Sarah Huoh
(SVP, 글로벌 커뮤니케이션)